These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32361788)

  • 1. The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy.
    Zheng Y; Hou G; Zhang G; Lan T; Yuan J; Zhang L; Yan F; Wang F; Meng P; Dun X; Li X; Chen G; Zhu Z; Wei D; He W; Yuan J
    Invest New Drugs; 2020 Dec; 38(6):1641-1652. PubMed ID: 32361788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible.
    Zheng Y; Lan T; Wei D; Zhang G; Hou G; Yuan J; Yan F; Wang F; Meng P; Yang X; Chen G; Zhu Z; Lu Z; He W; Yuan J
    Biomed Pharmacother; 2019 Aug; 116():109001. PubMed ID: 31146114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
    Lian H; Wu J; Hu Y; Guo H
    Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
    Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
    Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
    Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
    Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
    Angelergues A; Efstathiou E; Gyftaki R; Wysocki PJ; Lainez N; Gonzalez I; Castellano DE; Ozguroglu M; Carbonero IG; Flechon A; Borrega P; Guillot A; Balea BC; Le Moulec S; Esteban E; Munarriz J; Rubio G; Birtle AJ; Delanoy N; Bellmunt J; Oudard S
    Clin Genitourin Cancer; 2018 Aug; 16(4):e777-e784. PubMed ID: 29550200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 11. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
    Maines F; Caffo O; Veccia A; Trentin C; Tortora G; Galligioni E; Bria E
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):498-506. PubMed ID: 26318091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
    Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
    Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy.
    Yi X; Zhang J; Yan F; Lu Z; Huang J; Pan C; Yuan J; Zheng W; Zhang K; Wei D; He W; Yuan J
    Int J Oncol; 2016 Nov; 49(5):1911-1920. PubMed ID: 27633959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
    Mukhtar E; Adhami VM; Siddiqui IA; Verma AK; Mukhtar H
    Mol Cancer Ther; 2016 Dec; 15(12):2863-2874. PubMed ID: 27765854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Eskra JN; Schlicht MJ; Bosland MC
    Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.